Consultant

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

Retrieved on: 
Thursday, March 21, 2024
EUR, Brussels Stock Exchange, Exercise, Atlas, Capital commitment, Capital, Disclosure, Therapy, USD, Subscription business model, Consultant, Security (finance)

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.
  • Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 7,384,386,505 outstanding ordinary shares carrying voting rights (compared to 5,753,951,723 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Auri Signs a New Master Distributor Deal

Retrieved on: 
Wednesday, March 20, 2024
Crypto, Content development, Champ, Super heavyweight, Absorption, Gold, Publishing, Steam, Metal, NFT, Interview, Nano, Boxing, City, AURI, Olympic Games, Investment, Market, Water, Knockout, THC, Marketing, KO, Consultant

DALLAS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Auri Inc. (OTCPK: AURI) (the Company) signed with a national distributor for the Champ Knockout Line of Gummies.

Key Points: 
  • DALLAS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Auri Inc. (OTCPK: AURI) (the Company) signed with a national distributor for the Champ Knockout Line of Gummies.
  • Today, Auri Inc., is pleased to announce the signing of the Distribution Company in Dallas, Texas.
  • Auri Inc., is extremely excited to have a distributor with over 3,000 accounts, spread throughout North America.
  • Serving customers for over 30 years, and focused on delivering quality products to customers through over 25 states.

Toll Brothers Announces Model Home Grand Opening Event on March 23 at Regency at Tracy Lakes 55+ Community in Tracy, California

Retrieved on: 
Tuesday, March 19, 2024
Lifestyle, Friends, Freedom, Toll Brothers, Lake House, Bath, The Lake House, Consultant, Region, Design studio, Recreation, Family, Interstate Highway System, Hotel

The event will be held on Saturday, March 23 from 11 a.m. to 3 p.m. at 1650 Aloha Court in Tracy.

Key Points: 
  • The event will be held on Saturday, March 23 from 11 a.m. to 3 p.m. at 1650 Aloha Court in Tracy.
  • “We are thrilled to debut our new model homes in this very special community,” said Todd Callahan, Regional President of Toll Brothers in Northern California.
  • Toll Brothers Regency active-adult communities across the United States are planned with the active lifestyles of their residents in mind.
  • For more information on Regency at Tracy Lakes and Toll Brothers communities throughout California, call 844-790-5263 or visit TollBrothers.com/CA .

Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024

Retrieved on: 
Tuesday, March 19, 2024
Automation, QA/QC, PDA, Parenteral Drug Association, Convention, Growth, Consultant, Annual general meeting, Critical, Medical device

This year’s PDA Annual Meeting is at the core of the inaugural PDA Week that features many events including training, roundtables, presentations and tours that address the opportunities and challenges most relevant to the future of pharmaceutical microbiology.

Key Points: 
  • This year’s PDA Annual Meeting is at the core of the inaugural PDA Week that features many events including training, roundtables, presentations and tours that address the opportunities and challenges most relevant to the future of pharmaceutical microbiology.
  • Attendees will include global microbiology and QA/QC process professionals, regulators, academia and pharmaceutical industry consultants.
  • Rapid Micro’s booth, #435, will showcase the benefits of automating microbial quality control (“MQC”) testing using the Growth Direct® System software and technology for rapid incubation, detection and enumeration.
  • The presentation will include information on the new Growth Direct® Rapid Sterility Application, which is the only fully automated, non-destructive, growth-based platform for sterility testing.

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

Retrieved on: 
Tuesday, March 19, 2024
Consultant, Nephrology, Provisional application, XRX, Partnership, Chemistry, Kidney disease, Tablet, Orphan, Bryant University, University, EMA, Polycystic kidney disease, Trial of the century, Oxipurinol, MBA, GMP, Diet, PKD, Treatment, Society, Therapy, Patent, Rensselaer Polytechnic Institute, FDA, Marketing, Diagnosis, American Society of Nephrology, Uric acid, Pharmaceutical industry

Dr. Allen Davidoff, CEO of XORTX, stated, “2023 marked a year of substantial clinical, technological and regulatory progress, establishing the foundation for the Company’s 2024 goals.

Key Points: 
  • Dr. Allen Davidoff, CEO of XORTX, stated, “2023 marked a year of substantial clinical, technological and regulatory progress, establishing the foundation for the Company’s 2024 goals.
  • Each of these milestones permit the next step in the Company’s clinical development plan, being a “registration” clinical trial – XRX-OXY-201 in pursuit of accelerated approval and support of the Company’s lead program XRx-008 program for ADPKD.
  • Chemistry and Manufacturing, Clinical and Pre-Clinical Highlights – Produced drug substance for oxypurinol production and produced GMP drug substance; confirmed XORLO™ formulation, produced enhanced bioavailability and produced clinical supply of tablets for clinical trials.
  • August 29, 2023 – XORTX submitted an Orphan Drug Designation application to the EMA for the treatment of ADPKD.

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Retrieved on: 
Monday, March 18, 2024
Department of Defence, Food and Drug Administration, Burn, Learning, Patient, BVA, Sale, Nature, Statistics, Investment, Note, LVAD, ICU, Duke, Form, Blood volume, NIH, Heart failure, Length of stay, American College, Operation, Hand, Health, Food, Sepsis, Acceleration, Letter, Proxy, Knowledge, Research, Hospital, Acquisition, CLIA, Clinical study design, Family, FDA, Consultant, Annual general meeting, Diagnosis, RCT, Financial statement, Growth, Syncope, Mortality, National Institutes of Health, Nursing care plan, Bangladesh Technical Education Board, Net, Government, Physician, Medicine, Pharmaceutical industry

We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume measurement technology and the promise of what our rapid expansion means for both the company and the tens of millions of patients whose care we are eager to significantly improve. In every area 2023 and the strong start of 2024 has shown substantial progress for the company -- in revenue growth, new customer acquisitions, increasing utilization of our products by existing customers, next generation systems completed and under Food and Drug Administration (FDA) review, positive clinical studies, new patents granted and pending, successful National Institutes of Health (NIH) grant awards, Department of Defense (DoD) contracts awarded, and further research and development for groundbreaking products set to launch in subsequent fiscal years. I will detail below more in these areas but first wish to review why our company’s mission to commercialize the products that enable optimal patient care is so vital.

Key Points: 
  • Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.
  • Many of these markers are costly, some are invasive, and none are accurate – in contrast to Daxor’s proven 98% accurate system.
  • Care teams cannot effectively treat what they do not correctly diagnose, so our rapid accurate diagnostic test is a game-changer.
  • Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012.

Genius Group and OpenExO Sign Merger Agreement, Accelerating Plans to Build Global AI Education Group

Retrieved on: 
Monday, March 18, 2024
Organization, Boston Scientific, Acceleration, Education, AGI, AI, Human, Student, Founding, City, P&G, Ecosystem, Exo, Consultant, Singularity Group, Computer, Vodacom

This merger accelerates our plan to build a worldwide AI Education Group serving a global network of 100 Genius Cities and prepare 100 million students for our exponential future.

Key Points: 
  • This merger accelerates our plan to build a worldwide AI Education Group serving a global network of 100 Genius Cities and prepare 100 million students for our exponential future.
  • Salim is the author of the international bestseller “Exponential Organizations” and “Exponential Organizations 2.0, The New Playbook for 10x Growth & Impact”.
  • Salim serves on the Board of XPRIZE Foundation, which uses large-scale global incentive competitions to crowdsource solutions to the world’s grand challenges.
  • Genius Group’s CEO, Roger Hamilton said “Genius Group has recently announced plans to launch our Genius City model in Singapore, Dubai, Abu Dhabi.

New Salary.com® Survey Says Time for Pay Transparency Is Now

Retrieved on: 
Monday, March 18, 2024
Corporate services, Kenexa, Organization, Friction, Consultant, Health care, Communication, Insurance

The company today announced the results of its flagship 2024 Pay Practices Survey.

Key Points: 
  • The company today announced the results of its flagship 2024 Pay Practices Survey.
  • Their companies do not clearly communicate pay structure,” said David Turetsky, Chief Human Resources Officer and Vice President of Consulting at Salary.com.
  • “Our Pay Practices Survey shows a widespread disconnect.
  • Active employee communication is the fix.”
    Salary.com’s mission is to enable pay transparency.

LifeVantage Wraps Up Momentum Academy 2024 with a Focus on Entrepreneurship and Growth

Retrieved on: 
Monday, March 18, 2024
Momentum, Convention center, Health, Growth, Consultant, Female, Collection, Protandim, NFL

LifeVantage President and CEO, Steve Fife, reflected on the event's impact stating, "Momentum Academy was a resounding affirmation of our 'Rise Up' ethos.

Key Points: 
  • LifeVantage President and CEO, Steve Fife, reflected on the event's impact stating, "Momentum Academy was a resounding affirmation of our 'Rise Up' ethos.
  • Momentum Academy 2024 offered attendees an extraordinary chance to advance their businesses through an innovative format.
  • Recognition of rank advancements and seller titles added a celebratory flair, honoring the hard work and achievements of the LifeVantage community.
  • For more details on LifeVantage, upcoming events, and the newly launched products and incentives, visit www.lifevantage.com .

Notice to attend the Annual General Meeting of Olink Holding AB (publ)

Retrieved on: 
Friday, March 15, 2024
Exercise, Euroclear, Electoral roll, Category D, USD, Audit committee, Employment, Audit, Welfare, Policy, Annual general meeting, Tier, Minutes, Privacy, Person, Report, Consolidated, Plan, Proxy, Social Security, Meeting, Swedish, RSU, Consultant, Auditor, Committee, LTI, Annual report, European Parliament, Address, ADS, Units of paper quantity, Balance sheet, Security (finance)

UPPSALA, Sweden, March 15, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg.

Key Points: 
  • UPPSALA, Sweden, March 15, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg.
  • 559189-7755, are hereby given notice to attend the Annual General Meeting to be held at 4:00 p.m. CET on Friday the 19 April 2024, in the Company’s facilities at Salagatan 16A, Uppsala.
  • Shareholders who do not wish to attend the meeting in person may authorize a proxy to exercise their voting rights.
  • The power of attorney is proposed to be presented to the Chairman of the Meeting or another person whom the shareholder knows will attend the Annual General Meeting.